GN Store Nord stock
GN.COCPHGN Store Nord A/S, HealthcareISIN DK0010272632
55Score 55 out of 100, Neutral
Price and trend
87 / 100
Price history
+11% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 63).
The price is 1.7% below its 52-week high. Largest decline in 20 years: 90% (February 2007 to November 2008).
Chart figures for advanced users
- SMA 50$15.84
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$14.64
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)63
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.82
- The lowest closing price of the last twelve months.
- Resistance$18.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- GN Store Nord A/S belongs to the Medical (Devices) industry (Denmark) and, with a market value of $2.63B, is number 35 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.5B (down 6.1% year on year) and earnings of $96.8M (down 33.9%).
- For fiscal 2026, analysts expect on average revenue of $1.41B (down 43.6%) and adjusted earnings per share of −$0.05.
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 330 of 702 in Healthcare, median 53.
- Our model puts fair value at $14.77, with the price 22% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 70
Weaknesses
- Loss-makingLoss of $41.06M over the last 12 months.
- Earnings per share fallingDown 14.4% a year since 2020.Growth 24
- DilutionShare count up 13% since 2020.Capital allocation 46
Its standout strengths are technical analysis and momentum, while profitability and growth hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- low growth grade (crashed less often in the backtest)
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $10.55 and expensive above $24.61 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.4%. At 9.4% the fair value would be $12.60, at 7.4% it would be $17.77.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 6.1% on the prior year. Revenue has grown solidly since 2006, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 48%, operating 11%, net 4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 5 Nov 2026EPS reported $0.35 (expected $0.27)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 46.8% since 15 Oct 2026.
- Earnings per share
- −$0.05+46.8%
- Revenue
- $1.41B−0.4%
- Earnings per share
- $0.53−1.2%
- Revenue
- $1.48B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: −6.6%Adjusted EBITA margin guidance upgraded (partly due to DKK 100 million to DKK 150 million of tariff refunds), but revenue is now expected only in the lower half of the earlier range.
“This, together with an assumption of DKK 100 million to DKK 150 million of tariff refunds led us to upgrade our adjusted EBITA margin guidance for the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 20 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at GN Store Nord
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- AmbuAMBU-B.CO $3.4B71
- AxoGenAXGN $3.31B47
- TransMedics GroupTMDX $3.2B57
- iRhythm TechnologiesIRTC $3.1B30
- NeogenNEOG $2.44B41
- UFP TechnologiesUFPT $2.37B76
- Drägerwerk AG & Co. KGaADRW3.DE $2.31B66
- ElektaEKTA-B.ST $2.27B56
ETFs that hold GN Store Nord
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.23% | 0.23% | €321.86M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.18% | 0.30% | €813.64M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.14% | 0.30% | €3.45B |
Show 5 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 24 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.